BYSIHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 27 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores BeyondSpring, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BYSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 May 2023 | Baird | Maintains | Outperform | $4.00 → $1.25 |
| 2 Dec 2021 | B of A Securities | Downgrade | Underperform | — |
| 2 Dec 2021 | Jefferies | Downgrade | Hold | — |
| 1 Dec 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 20 Sept 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Sept 2021 | Baird | Initiates | Outperform | — |
| 4 Aug 2021 | HC Wainwright & Co. | Upgrade | Buy | — |
| 5 Apr 2021 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Jan 2021 | B of A Securities | Initiates | Buy | — |
| 29 Dec 2020 | Evercore ISI Group | Initiates | Outperform | — |
| 15 June 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Feb 2020 | Jefferies | Initiates | Buy | — |
| 10 Jan 2020 | Nomura | Initiates | Buy | — |
| 10 Jan 2020 | Nomura Instinet | Initiates | Buy | — |
| 3 Dec 2019 | William Blair | Initiates | Outperform | — |
| 22 June 2018 | Maxim Group | Maintains | Buy | — |
| 4 Apr 2017 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BYSI appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, BeyondSpring, Inc. returned −71.6% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 94% of US stocks
Cheaper than 71% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 52% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BeyondSpring, Inc. has a market value of $19.0M and an enterprise value of $12.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$23.1M.
Free cash flow in the twelve months to 30 June 2026: −$16.7M.
Trailing P/E: −24.2×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BeyondSpring, Inc. employs 44 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BeyondSpring, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of BeyondSpring Inc.’s shareholder/analyst call prepared remarks.
Why it matters — The transcript provides BYSI watchers with the company’s prepared remarks from a shareholder and analyst call.
BeyondSpring Inc. (BYSI) discussed its FDA Fast Track designation and a strategic transaction for Plinabulin in post-ICI non-squamous non-small cell lung cancer (NSCLC) in a transcript of company remarks.
Why it matters — A BYSI watcher would care because FDA Fast Track status and a strategic transaction could represent meaningful progress for Plinabulin's development in this non-squamous NSCLC indication.
BeyondSpring announced that the FDA granted Fast Track designation to Plinabulin combined with docetaxel for treating advanced or metastatic non-squamous non-small cell lung cancer in patients who progressed after prior anti-PD-(L)1 antibody and platinum-based chemotherapy. This population is being studied in the company's global Phase 3 DUBLIN-4 trial, which the company says it is advancing toward a planned interim analysis.
Why it matters — FDA Fast Track designation may accelerate development and review of Plinabulin, a key pipeline candidate, as BeyondSpring works toward the interim analysis of its DUBLIN-4 trial.
BeyondSpring reported its second-quarter 2026 financial results and provided a corporate update. The update highlights ASCO 2026 data demonstrating a long-term survival benefit of Plinabulin/Docetaxel and Pembrolizumab in metastatic non-small cell lung cancer following progression on first-line immune checkpoint inhibitor therapy.
Why it matters — BYSI watchers would care because the ASCO 2026 data provides encouraging evidence of a long-term survival benefit for Plinabulin-based combinations in a difficult-to-treat NSCLC patient population.
Of the 2 analysts covering BeyondSpring, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BeyondSpring, Inc. 20 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, BeyondSpring, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
No analyst covering BeyondSpring, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYSI are extrapolating price history, which says nothing about the business.
BeyondSpring, Inc. returned -71.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care.
The most recent item we track (Seeking Alpha, 13 Oct 2026): "BeyondSpring Inc. (BYSI) Shareholder/Analyst Call Prepared Remarks Transcript". Seeking Alpha published a transcript of BeyondSpring Inc.’s shareholder/analyst call prepared remarks.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with an emphasis on immuno-oncology and cancer-supportive care. The company’s core programs center on Plinabulin, a lead candidate being studied for use in non-small cell lung cancer and in the prevention of chemotherapy-induced neutropenia, a condition that can complicate cancer treatment. BeyondSpring also operates a TPD platform that supports the discovery and development of therapeutic agents and new chemical entities. Its work is directed at addressing unmet needs in cancer care through targeted drug development and clinical research. Headquartered in Florham Park, New Jersey, BeyondSpring Inc. plays a specialized role in the biotechnology market as a research-driven company advancing late-stage and early-stage therapeutic candidates.
CEO Dr. Lan Huang Ph.D. · 44 employees · United States · https://beyondspringpharma.com
